Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 aggregate principal amount of its 4.70% Senior Notes, Series A, due December 1, 2023 (the “Series A Notes”) and (ii) $40,000,000 aggregate principal amount of its 4.93% Senior Notes, Series B, due December 1, 2025 (the “Series B Notes” and, together with the Series A Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 205,000,000 aggregate principal amount of its 4.706.28% Senior Notes, Series A, due December 1June 26, 2023 2015 (the “Series A Notes”) and (iib) $40,000,000 145,000,000 aggregate principal amount of its 4.936.72% Senior Notes, Series B, due December 1June 26, 2025 2018 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Notes being hereinafter collectively referred to as the “Notes”, as amended, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and Exhibit 1 or Exhibit 2, as the Series B Notes shall be substantially in the form set out in Schedule 1(b)case may be. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 6.23% guaranteed senior notes due August 11, 2011 in an aggregate principal amount of its 4.70% Senior Notes, Series A, due December 1, 2023 $50,000,000 (the “Series A Notes”) and (ii) $40,000,000 6.23% guaranteed senior notes due August 11, 2015 in an aggregate principal amount of its 4.93% Senior Notes, Series B, due December 1, 2025 $50,000,000 (the “Series B Notes” Notes and, together with the Series A Notes, as amendedthe Notes, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, 14 of this Agreement or the “Notes”Other Agreements (as hereinafter defined)). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-A and Exhibit 1-B, respectively, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References The Series of a Note refers to whether a “Schedule” are references to Note is a Schedule attached to this Agreement unless otherwise specified. References to Series A Note or a “Section” are references to a Section of this Agreement unless otherwise specifiedSeries B Note.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 25,000,000 aggregate principal amount of its 4.705.30% Senior Notes, Series A, due December 1, 2023 2039 (the “Series A Notes”) and (iib) $40,000,000 25,000,000 aggregate principal amount of its 4.935.59% Senior Notes, Series B, due December 1, 2025 2054 (the “Series B Notes” and, and together with the Series A Notes, as amendedthe “Notes”, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form forms set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 500,000,000 aggregate principal amount of its 4.70senior notes consisting of (a) $250,000,000 aggregate principal amount of its 3.24% Series A Senior NotesNotes due July 10, Series A, due December 1, 2023 2026 (the “Series A Notes”) and (iib) $40,000,000 250,000,000 aggregate principal amount of its 4.933.45% Series B Senior NotesNotes due July 10, Series B, due December 1, 2025 2029 (the “Series B Notes” and, together with the Series A Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in and the form set out in Schedule 1(a) Series B Notes are hereinafter referred to collectively as the “Notes.” The Series A Notes and the Series B Notes shall be substantially in the form forms set out in Schedule Schedules 1(a) and 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize has authorized the issue and sale of (i) $60,000,000 100,000,000 aggregate principal amount of its 4.70Senior Notes consisting of (i) $50,000,000 aggregate principal amount of its 5.72% Senior Notes, Series A, due December 1September 30, 2023 2019 (the “Series A Notes”) and (ii) $40,000,000 50,000,000 aggregate principal amount of its 4.935.72% Senior Notes, Series B, due December 1March 30, 2025 2020 (the “Series B Notes” and, together with the Series A Notes, as amendedthe “Notes”, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”13 of this Agreement). The Series A Notes shall will be substantially in the form set out in Schedule Exhibits 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b), with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 40,000,000 aggregate principal amount of its 4.705.61% Senior Notes, Series A, due December 1September 15, 2023 2034 (the “Series A Notes”) and (iib) $40,000,000 30,000,000 aggregate principal amount of its 4.935.91% Senior Notes, Series B, due December 1, 2025 2053 (the “Series B Notes” and, and together with the Series A Notes, as amendedthe “Notes”, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form forms set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 aggregate principal amount of its 4.702.48% Senior Notes, Series A, due December 1August 15, 2023 2031 (the “Series A Notes”) and (iib) $40,000,000 aggregate principal amount of its 4.932.63% Senior Notes, Series B, due December 1June 15, 2025 2033 (the “Series B Notes” and”, together with the Series A Notes, as amendedthe “Notes”, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form forms set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 57,000,000 aggregate principal amount of its 4.707.81% Series E Senior NotesNotes due April 3, Series A, due December 1, 2023 2016 (the “Series A E Notes”) and (iib) $40,000,000 43,000,000 aggregate principal amount of its 4.938.24% Series F Senior NotesNotes due April 3, Series B, due December 1, 2025 2019 (the “Series B F Notes” and, together with the Series A E Notes, as amendedcollectively, restated or otherwise modified from time the “Notes”, such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A E and Series F Notes shall be substantially in the form forms set out in Schedule 1(a) Exhibit 1A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 250,000,000 aggregate principal amount of its 4.703.69% Senior Unsecured Notes, Series A, due December 1November 21, 2023 2018 (the “Series A Notes”) and (ii) $40,000,000 250,000,000 aggregate principal amount of its 4.934.32% Senior Unsecured Notes, Series B, due December 1November 21, 2025 2023 (the “Series B Notes” and, together with ”) (the Series A Notes and the Series B Notes are collectively referred to as the “Notes”, as amended, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule Exhibit 1(a) and Exhibit 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 50,000,000 aggregate principal amount of its 4.706.50% Senior Guaranteed Notes, Series A, due December 1August 7, 2023 2015 (the “Series A Notes”) and (iib) $40,000,000 50,000,000 aggregate principal amount of its 4.937.10% Senior Guaranteed Notes, Series B, due December 1August 7, 2025 2023 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Notes are hereinafter collectively referred to as the “Notes, as amended, restated or otherwise modified from time ,” such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 50,000,000 aggregate principal amount of its 4.702.71% Series A Senior NotesUnsecured Notes due July 30, Series A, due December 1, 2023 2019 (the “Series A Notes”) and (iib) $40,000,000 150,000,000 aggregate principal amount of its 4.933.64% Series B Senior NotesUnsecured Notes due July 30, Series B, due December 1, 2025 2024 (the “Series B Notes” and, together with the Series A Notes, as amendedcollectively, restated or otherwise modified from time the “Notes”, such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form respective forms set out in Schedule Exhibit 1(a) and Exhibit 1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 100,000,000 aggregate principal amount of its 4.706.26% Senior Notes, Series A, due December 1August 3, 2023 2014 (the “Series A Notes”) and (iib) $40,000,000 300,000,000 aggregate principal amount of its 4.936.44% Senior Notes, Series B, due December 1August 3, 2025 2017 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Notes are hereinafter collectively referred to as the “Notes, as amended, restated or otherwise modified from time ,” such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 50,000,000 aggregate principal amount of its 4.705.68% Senior Notes, Series A, due December 17, 2023 2017 (the “Series A Notes”) and (ii) $40,000,000 25,000,000 aggregate principal amount of its 4.935.68% Senior Notes, Series B, due December 17, 2025 2018 (the “Series B Notes,” and, and together with the Series A Notes, as amendedare collectively the “Notes”, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes of either series issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-A and Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.